SCHEMBL2542850

SCHEMBL2542850

COc1cc(C(=O)NC2CC2)ccc1Nc1ncc2c(n1)N(C1CCC(F)(F)C1)CC(C)(C)C(=O)N2C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 18/20 0.68
BRD4 O60885 8/20 0.68
BRDT Q58F21 7/20 0.68
RAD52 P43351 1/20 0.57
PLK3 Q9H4B4 3/20 0.56
PLK2 Q9NYY3 1/20 0.56
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
PRKCG P05129 1/20 0.55
CLK2 P49760 1/20 0.55
RPS6KA3 P51812 1/20 0.55
NEK4 P51957 1/20 0.55
PTK2 Q05397 1/20 0.55
CAMK2G Q13555 1/20 0.55
CAMK2D Q13557 1/20 0.55
SRPK1 Q96SB4 1/20 0.55
PRKD2 Q9BZL6 1/20 0.55
CSNK1G1 Q9HCP0 1/20 0.55
CSNK1G3 Q9Y6M4 1/20 0.55
DCLK1 O15075 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2542847 1.00 PLK1 (0.68) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2541815 0.97 PLK1 (0.66) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2547864 0.97 PLK1 (0.66) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2540237 0.95 PLK1 (0.62) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2548155 0.95 PLK1 (0.62) PLK1BRD4BRDTRAD52PLK3
SCHEMBL12238239 0.95 PLK1 (0.62) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2543954 0.93 PLK1 (0.68) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2546636 0.93 PLK1 (0.68) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4078755 0.91 PLK1 (0.57) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2397030 0.90 PLK1 (0.67) PLK1BRD4BRDTRAD52PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140018352-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-16 US claimed
EP-2190849-B1 4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES VERTEX PHARMA (US) 2013-11-20 EP claimed
US-8461149-B2 Compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-11 US claimed
US-20110263575-A1 Compounds Useful as Protein Kinase Inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2011-10-27 US claimed
EP-2190849-A2 COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS Vertex Pharmceuticals Incorporated (US) 2010-06-02 EP claimed
WO-2009023269-A2 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-19 WO claimed
US-20140018352-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-16 US disclosed
EP-2190849-B1 4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES VERTEX PHARMA (US) 2013-11-20 EP disclosed
US-8461149-B2 Compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-11 US disclosed
US-20110263575-A1 Compounds Useful as Protein Kinase Inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2011-10-27 US disclosed
EP-2190849-A2 COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS Vertex Pharmceuticals Incorporated (US) 2010-06-02 EP disclosed
WO-2009023269-A2 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018352-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MAP3K20, PRKCH, PACSIN2 PLK1 28/4885BRD4 868/4885BRDT 746/4885
US-20110263575-A1 Compounds Useful as Protein Kinase Inhibitors MAP3K20, PRKCH, PACSIN2 PLK1 28/4885BRD4 868/4885BRDT 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.